Susquehanna International Group
ITCI

Susquehanna International Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Susquehanna International Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,286
Closed -$1.16M – 13714
2024
Q4 		$776K Sell
9,286
-17,854
-66% -$1.47M ﹤0.01% 7592
2024
Q3 		$1.99M Sell
27,140
-179,564
-87% -$13.5M ﹤0.01% 5279
2024
Q2 		$14.2M Buy
206,704
+158,530
+329% +$11M ﹤0.01% 2089
2024
Q1 		$3.33M Sell
48,174
-98,617
-67% -$6.78M ﹤0.01% 4305
2023
Q4 		$10.5M Buy
+146,791
New +$8.44M ﹤0.01% 2578
2023
Q3 		– Sell
-28,088
Closed -$1.64M – 13188
2023
Q2 		$1.78M Sell
28,088
-11,315
-29% -$705K ﹤0.01% 5390
2023
Q1 		$2.13M Buy
39,403
+35,564
+926% +$1.72M ﹤0.01% 4994
2022
Q4 		$203K Sell
3,839
-30,700
-89% -$1.54M ﹤0.01% 10086
2022
Q3 		$1.61M Buy
34,539
+29,682
+611% +$1.55M ﹤0.01% 5431
2022
Q2 		$277K Sell
4,857
-1,282
-21% -$72.7K ﹤0.01% 9784
2022
Q1 		$376K Sell
6,139
-59,915
-91% -$3.11M ﹤0.01% 9705
2021
Q4 		$3.46M Sell
66,054
-149,117
-69% -$6.26M ﹤0.01% 4396
2021
Q3 		$8.02M Sell
215,171
-52,106
-19% -$1.81M ﹤0.01% 3198
2021
Q2 		$10.9M Buy
267,277
+41,028
+18% +$1.52M ﹤0.01% 2790
2021
Q1 		$7.68M Buy
226,249
+14,590
+7% +$506K ﹤0.01% 3202
2020
Q4 		$6.73M Sell
211,659
-102,565
-33% -$2.7M ﹤0.01% 2992
2020
Q3 		$8.06M Buy
314,224
+72,502
+30% +$1.65M ﹤0.01% 2455
2020
Q2 		$6.21M Sell
241,722
-45,177
-16% -$915K ﹤0.01% 2716
2020
Q1 		$4.41M Buy
286,899
+279,931
+4,017% +$6.08M ﹤0.01% 2751
2019
Q4 		$239K Sell
6,968
-33,571
-83% -$403K ﹤0.01% 8443
2019
Q3 		$303K Buy
40,539
+20,805
+105% +$199K ﹤0.01% 8283
2019
Q2 		$256K Buy
+19,734
New +$253K ﹤0.01% 8629
2018
Q4 		– Sell
-98,127
Closed -$1.58M – 10145
2018
Q3 		$2.13M Sell
98,127
-26,699
-21% -$558K ﹤0.01% 3874
2018
Q2 		$2.21M Sell
124,826
-26,578
-18% -$540K ﹤0.01% 3847
2018
Q1 		$3.19M Buy
151,404
+46,818
+45% +$912K ﹤0.01% 3163
2017
Q4 		$1.51M Sell
104,586
-1,000,441
-91% -$15.4M ﹤0.01% 4447
2017
Q3 		$17.4M Buy
1,105,027
+991,287
+872% +$14.5M 0.01% 1328
2017
Q2 		$1.41M Buy
113,740
+92,297
+430% +$1.07M ﹤0.01% 4547
2017
Q1 		$348K Sell
21,443
-98,820
-82% -$1.43M ﹤0.01% 7118
2016
Q4 		$1.81M Buy
+120,263
New +$1.7M ﹤0.01% 4265
2016
Q1 		– Sell
-5,143
Closed -$171K – 9794
2015
Q4 		$277K Sell
5,143
-37,664
-88% -$1.9M ﹤0.01% 7840
2015
Q3 		$1.71M Buy
42,807
+15,045
+54% +$491K ﹤0.01% 4583
2015
Q2 		$887K Buy
+27,762
New +$704K ﹤0.01% 6467
2014
Q3 		– Sell
-10,181
Closed -$172K – 10035
2014
Q2 		$172K Buy
+10,181
New +$168K ﹤0.01% 9175

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Susquehanna International Group's ITCI Position: Q1 2025 in Review

Susquehanna International Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 9,286 shares — an estimated $1.16M sold.

Susquehanna International Group first reported a position in ITCI in Q2 2014 and held it in 34 quarters. The position peaked at $17.4M in Q3 2017. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Susquehanna International Group reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 9,286 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $1.16M.
  • Susquehanna International Group first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 34 quarters.
  • Susquehanna International Group's Intra-Cellular Therapies Inc. position peaked at $17.4M in Q3 2017.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.